Belgium’s PanTera has begun construction of its Actinium Production Centre (APC) in Mol, northern Belgium, a dedicated facility that will produce the medical radioisotope actinium-225 (Ac-225) for use in targeted alpha therapy against cancer.

The company said in a statement that the facility will become “a cornerstone” for the global supply of the radioisotope.

PanTera said the facility is expected to become operational in 2028 with the first commercial supplies of Ac-225 scheduled for 2029. Once fully ramped up, the plant will be capable of producing hundreds of curies of Ac-225 annually, ensuring a stable global supply of the isotope for pharmaceutical companies and patients. The curie is a unit of radioactivity.